To check whether NRF2 and HER4 follow the same expression pattern in different cell lines and cancer models, we retrieved and analyzed the microarray gene expression data and profiles of ERL resistant NSCLC PC9 cells [44] treated with ERL or histone deacetylase (HDAC) inhibitor YF454A alone or their combination (Figure 4C). This evidence concerns the gene ERBB4 and cancer.